SACRAMENTO, CA (PRWEB) January 31, 2006 -- Telomolecular Corp., a biotechnology company, that develops biopharmaceutical therapies designed to treat aging and age-related disease, today announced the signing of a global licensing agreement with UNeMed, Omaha Nebraska, the licensing agent for the University of Nebraska Medical Center, a leading licensor of advanced medical and biomedical products and patents. Under the agreement, Telomolecular is granted the right to perform research and development, and commercialize technologies, that may lengthen chromosomal telomeres in living animals, based upon the University of Nebraska Medical Center's proprietary poly (D,L-lactide-co-glycolide) (PLGA) biodegradable nanoparticles.

Telomolecular intends to use these licensing rights to develop new types of pharmaceutical products that are useful in the treatment of human aging and in the correction of certain age-related diseases, such as atherosclerosis, arteriosclerosis, liver cirrhosis, Progeria, and many other presently incurable degenerative disorders.

According to Mr. Matthew A. Sarad, Chief Executive Officer of Telomolecular, “PLGA biodegradable nanoparticles is a new and important gene therapy tool. Our company hopes, with this platform, to develop market appropriate technologies of social and historical significance. We look forward to growing the relationship between Telomolecular, UNeMed, and the University of Nebraska Medical Center, in exciting ways.”

"The nanoparticle formulation and material release technology is ideally suited for the therapeutic applications described by Telomolecular Corporation," said UNeMed's President, Dr.Thomas McDonald. "We look forward to continuing to foster a productive and growing relationship between the University of Nebraska Medical Center and Telomolecular in developing this as well as other technologies of mutual interest."

About PLGA Biogegradable Nanoparticles
PLGA biodegradable nanoparticles are an FDA approved gene therapy product that has been extensively investigated for sustained and targeted/localized delivery of different agents including plasmid DNA, proteins and peptides and low molecular weight compounds. Molecules much too large for traditional gene therapies can be encapsulated and delivered with PLGA. PLGA is non-toxic, does not illicit an immune response, and causes high transfection rates.

About UNeMed
UNeMed is a service-oriented corporation that functions as the interface between the University of Nebraska Medical Center (UNMC) and industry to promote UNMC technology development and economic development in Omaha. In cooperation with UNMC inventors and the Intellectual Property Office, UNeMed drives and facilitates the transfer of the technologies invented on campus into the marketplace. UNeMed Corporation was established in 1992 as a for-profit subsidiary of UNMC.

About Telomolecular
Telomolecular develops nanotechnologies capable of delivering large-molecule proteins across human cell membranes. The corporation's primary focus is on the delivery of therapeutic agents that lengthen and repair chromosomal telomeres in living animals. Successful therapies based on this tactic may offset, and potentially reverse, many devastating age-related diseases and perhaps address the symptoms and signs recognized as human aging.

Telomolecular Investor Relations
Matthew A. Sarad
(916) 410-8681